Nurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on Friday

Key Points

• Nurix Therapeutics is set to release its Q3 2025 financial results on **October 10, 2025**, with anticipated earnings of ($0.84) per share and revenue of $16.06 million.
• In its previous earnings report, Nurix reported ($0.52) EPS and revenue of $44.06 million, surpassing analysts' estimates significantly.
• The stock currently has a market capitalization of $694.17 million and a consensus rating of "Moderate Buy" from analysts with a price target of about **$29.07**.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) is projected to post its Q3 2025 results before the market opens on Friday, October 10th. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $16.06 million for the quarter. Investors may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, October 10, 2025 at 4:00 PM ET.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. The business had revenue of $44.06 million during the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $9.08 on Friday. The stock has a market capitalization of $694.17 million, a price-to-earnings ratio of -3.48 and a beta of 2.33. Nurix Therapeutics has a 1-year low of $8.18 and a 1-year high of $29.56. The business's fifty day moving average price is $9.73 and its 200-day moving average price is $10.73.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Stephens reissued an "overweight" rating and issued a $30.00 target price on shares of Nurix Therapeutics in a report on Thursday, July 10th. Oppenheimer reiterated an "outperform" rating and issued a $30.00 price objective (down previously from $32.00) on shares of Nurix Therapeutics in a research note on Thursday, July 31st. Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. UBS Group decreased their price target on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, July 10th. Finally, Morgan Stanley set a $16.00 price target on shares of Nurix Therapeutics and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.07.

Insider Activity at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the sale, the insider directly owned 69,023 shares of the company's stock, valued at $828,966.23. This represents a 5.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 5,402 shares of Nurix Therapeutics stock in a transaction on Friday, August 1st. The shares were sold at an average price of $11.03, for a total transaction of $59,584.06. Following the transaction, the chief financial officer owned 35,512 shares in the company, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,014 shares of company stock worth $163,014 in the last ninety days. Insiders own 7.40% of the company's stock.

Institutional Trading of Nurix Therapeutics

Several institutional investors have recently made changes to their positions in NRIX. Tower Research Capital LLC TRC raised its stake in Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company's stock valued at $73,000 after purchasing an additional 3,475 shares during the period. Sei Investments Co. bought a new stake in shares of Nurix Therapeutics during the second quarter valued at approximately $158,000. Creative Planning purchased a new position in shares of Nurix Therapeutics in the second quarter worth $187,000. Man Group plc purchased a new position in shares of Nurix Therapeutics in the second quarter worth $322,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Nurix Therapeutics by 17.9% during the second quarter. The Manufacturers Life Insurance Company now owns 37,214 shares of the company's stock worth $424,000 after acquiring an additional 5,647 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.